RAD51D Gene Mapping Breakthrough Resolves Cancer Risk Test Ambiguities
A detailed genetic map measuring the effects of 6,888 variants of the RAD51D gene was published on October 3, 2026, in Nature Communications, offering new clarity for hereditary breast and ovarian cancer screening, mondosanita.it reported. Researchers moved beyond simply sequencing DNA to directly testing how specific genetic differences impact cellular function, tackling the persistent problem of Variants of Uncertain Significance (VUS) in clinical diagnostics.
When genetic tests reveal a VUS, laboratories have identified a DNA modification, but current scientific data cannot confirm whether the alteration is harmless or tied to disease risk. Genes like RAD51D act as tumor suppressors and play a vital role in homologous recombination, one of the primary mechanisms cells use to repair double-strand DNA breaks. Understanding whether a variant disrupts this repair system helps determine if genome instability will follow.
Laboratory Saturation Mutagenesis Puts Variants Under Pressure
To evaluate thousands of alterations at once, the study authors engineered 6,888 distinct versions of the RAD51D gene and introduced them into cells lacking a functional copy of the gene. Researchers then exposed these modified cells to olaparib, a PARP inhibitor medication that specifically targets and destroys cells with homologous recombination defects. This functional stress test allowed the team to separate normal, efficient gene behavior from impaired or lost function.
Meanwhile, 1,038 variants demonstrated a complete loss of function, and 536 showed an intermediate behavioral response. The experiment revealed that mutations concentrated in regions responsible for DNA binding and ATPase activity, which utilizes the energy molecule ATP, were far less tolerant to change than other parts of the protein.
Clinical Database Integration Identifies 85 Loss-of-Function Variants
The research team applied their experimental map to 789 missense variants of RAD51D cataloged in the ClinVar database with conflicting or uncertain clinical interpretations. After filtering out variants likely to disrupt RNA splicing or yield ambiguous functional scores, investigators evaluated 672 variants with high confidence. Approximately 87% of those evaluated functioned normally, while 85 variants confirmed a loss of function.
Independent laboratory testing on 70 additional variants observed in clinical breast and ovarian cancer cases showed strong concordance with the large-scale screening data. The research team calibrated the assay to yield strong evidence for or against a pathogenic classification.
Clinical Integration and Diagnostic Limitations
Despite the high-throughput map’s precision, researchers emphasized that a functional test result does not constitute a standalone medical diagnosis. Interpreting a genetic variant still requires analyzing population frequency data, family medical histories, clinical records, and independent molecular predictions. The new functional map adds a critical layer of evidence, but clinicians must integrate it with broader diagnostic criteria before making definitive patient care decisions.
Frequently Asked Questions About the RAD51D Study
What specific gene does the October 2026 study examine?
The study published on October 3, 2026, in Nature Communications investigates the RAD51D gene, which is involved in DNA repair and associated with hereditary breast and ovarian cancer risks.
How many genetic variants did the researchers test?
Researchers measured the cellular effects of 6,888 different variants of the RAD51D gene by introducing them into engineered cells and exposing them to the PARP inhibitor olaparib.
What did the analysis of ClinVar database variants reveal?
Out of 672 evaluable variants with previously uncertain significance, the screening showed that roughly 87% functioned normally, while 85 variants exhibited a distinct loss of function.
Related reading